Radiation-related skin irritation
Potential benefit studied: Reduced radiation-dermatitis severity
Supporting researchThis is cancer research, not a product treatment claim. These studies do not establish that Longevity or Mobility prevents, treats or cures cancer.
A randomized human trial found that oral curcumin reduced the severity of radiation dermatitis in breast-cancer patients.
A randomized trial gave 30 breast-cancer patients 6 g daily curcumin or placebo during radiotherapy and measured dermatitis severity.
Neither trial tested Longevity, and its final 1,000 mg daily curcumin amount differs from the studied regimen. These findings do not support a retail-product radiation-protection claim. Skin care during radiotherapy should follow the oncology team's instructions.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.